Kelso Pharma, the growing specialty pharma business backed by Apposite Capital, the healthcare specialist private equity investor, today (19 February 2025) announces the acquisition… Read More
Issued: London, Tuesday 6th February 2024 Announced today, ALTURiX – a rapidly expanding British pharmaceutical company – has acquired the exclusive rights to three… Read More
Bedwetting, also known as nocturnal enuresis, is a common condition where urine is passed during sleep. It can affect children of any age and… Read More
Issued: London, Wednesday 25th October 2023 Announced today, ALTURiX – a rapidly-growing British pharmaceutical company – has launched CEYESTO® 1mg/ml Melatonin Oral Solution in… Read More
ALTURiX are pleased to announce the launch of DEMOVO® Desmopressin 360mcg/ml oral solution. An additional option for the treatment of both nocturnal enuresis and… Read More
On April 28th 1998, our original founder, John Kettleborough, secured the rights to our three heritage products marking the beginning of an incredible journey… Read More
MEDICAL AND TRADE PRESS RELEASE: Issued Tuesday 22nd November 2022 Announced today, ALTURiX – a rapidly-growing British pharmaceutical company – has been granted… Read More
Register here… Read More
The global health sector accounts for around 4% of emissions worldwide. That’s more than shipping or aviation. The NHS carbon footprint totals 25 million tonnes… Read More
Issued: London, Monday 30th May 2022 Announced today, ALTURiX – a rapidly-growing British pharmaceutical company – has acquired the exclusive rights to liothyronine for… Read More
To enter the product area of this site you need to confirm you are a Healthcare Professional.
I am a Healthcare ProfessionalIf you are not a Healthcare Professional, please return to the main site.
I am not a Healthcare Professional If you are not a Healthcare Professional and require further information about any of our products, please speak to your doctor, pharmacist or nurse.